---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037369"
form_type: "8-K"
ticker: "SEER"
cik: "0001726445"
company_name: "Seer, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:28:53.073288+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Seer Q3 revenue $4.2M (+5% YoY), net loss $21.1M; guides to lower half of FY range

## Summary
- Revenue $4.2M (+5% YoY); product revenue $3.3M incl $1.4M related party; service $536K; grant $348K.
- Net loss $21.1M vs $24.0M YoY; operating expenses $28.0M with $8.3M stock-based compensation.
- Cash and investments $380.8M at Sep 30, 2023.
- FY 2023 revenue guided to lower half of $16-18M range due to ongoing macroeconomic headwinds.
- Expanded geographically with Danyel Biotech (Israel) and GeneTiCA (Eastern Europe); added Panome Bio as Center of Excellence.

## SEC filing metadata
- accession: 0001628280-23-037369
- form_type: 8-K
- ticker: SEER
- cik: 0001726445
- company_name: Seer, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726445/000162828023037369/0001628280-23-037369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726445/000162828023037369/seer-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037369
- JSON: https://secwatch.observer/filing/0001628280-23-037369.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037369.txt

## Key facts
- Earnings Releases
  Seer, Inc. reported third quarter ended September 30, 2023 results: revenue $4.2 million, net income $21.1 million. Guidance lowered.
  - Period: third quarter ended September 30, 2023
  - Revenue: $4.2 million
  - Net income: $21.1 million
  - Guidance: lowered
  - Result: reported results
  source text: a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights • Achieved revenue of $4.2 million for the third quarter of 2023, an increase of 5% over the prior year period • Expanded geographically with two new partners - Danyel Biotech in Israel and GeneTiCA in Eastern
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726445/000162828023037369/0001628280-23-037369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.